			Notice of Refere	enc s Cited	1	Application/Control e8/403,736 / 6/6  Examin r  Eleaner Serbello	No. 93,688	Applicant(s)/Pat Reexaminati n LI ET AL. Art Unit	nt Und r	
				·	U.S. PA	TENT DOCUMENTS				
	*		DOCUMENT NO.	DATE		NAME	CLASS	SUBCLASS	DOCUMEN SOURCE **	
97P		√ <sub>A</sub>	6,080,728	Jun. 2000	Mixson		514	44		
		В	·							
		С	·							
		D		<u> </u>						
		E								
		F								
		G	·							
		н								0
		1								
		J				,				
		к								0
		ı								
		м				•				
					FOREIGN	PATENT DOCUMENTS			DOCUMEN	vr -
	*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	SOURCE	
		N							0	
		0								
		P							0	<u> </u>
		q	·							
		R								
		s								
		Т					·			
.					NON-PA	TENT DOCUMENTS		····	DOCUME	NT
16/8/05	*		DOC	CUMENT (Includir	ng Author, Title	Date, Source, and Pertir	nent Pages)		APS	OTHER
		\ \ \	Dang et al.Gene Therapy Feb 1999	and Translation	nal Cancer Th	erapy, Clinical Cance	r Research, V	ol 5, 471-474,	0	
		<b>/</b>	Eck, S.L et al. , 1996, Cl Therapeutics. page 77-10	n. 5. Gene Base 1e <del>k, et al</del> .	d Therapy,G	oodman & Gillman's T	he Pharmaco	logical basis of	0	0
(		/w	Robbins, Review: Viral Ve	ectors for gene t	herapy, Trend	ds in Biotechnology, V	/ol. 16, pages	35-40 <sub>j</sub> , Jan. 1998		0
		х							0	0

A copy of this reference is not being furnished with this Office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)

"APS encompasses any electronic search i.e. text, image, and Commercial Databases.

J.S. Patent and Trademark Office

"ICL892 (Rev. 03-98)"

N tice of R fer nces Cited

Sutt D. Priels 12/9/05

Part of Paper No. 9

PTO-1449

FORM (REV.		1449 (Modified)						OMMERC RK OFFIC		ATTY. DOCKE	T NO	. А	PPLICAT	ION N	Ο.
		LIST OF REF	EREN	CES C	TED I	BY API	PLICAN	r							
		(Use	sever	al shee	ts if nec	essary)	1						10/693,	688	
	· <u>.</u>		-			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		<del></del>		A2778A-US		94	19672) <del>2403.736</del>		
			**							APPLICANT					
		<del></del>								Hong LI et al.					
								<del></del>		FILING DATE		G	ROUP		
								·		October 26, 199	9	1	633 .		•
-						U.S.	PATEN	T DOCUM	IENT	S					
*EXAMINER			DOC	CUMENT N	UMBER			DATE		NAME		CLASS	SUBCLAS	S FILE	DIG DATE VROPRIATE
														_	
								•							
	<u> </u>				<del> </del>	↓	<u> </u>						_		
		<b> </b>		ļ	-	-	-			·		ļ .			· · · · · · · · · · · · · · · · · · ·
	<u> </u>				<u> </u>	OPEI	CNI DAT	ENT DOC	UNAE	AUTO		<u> </u>			_
	Τ	Π	DOC	UMENT N		OKEI	JN FAT	DATE	OME	COUNTRY	٠,	ZASE	SUBCLASS	TRANS	LATION
	·											2,33	·	YES	NO
									<u> </u>						
									ļ						
				ļ	ļ					****					
					-	-									<u> </u>
	ļ					<del> </del>					-  -			ļ <u>.</u>	<del> </del>
	<u></u>		THE	RDOC	UMEN	TS (In	cluding 4	Author Tit	le Da	ite, Pertinent Page	s etc	<u>, l</u>		L	
		n								er model with type				····	
SDP		murine angios 166(10):6212-	tatin ar	ıd il-12	: a role	for con	nbined ar	nit-angioge	nesis a	and immunotherap	y," <i>J</i> . A	moviru Immune	ol., May 15	, 2001,	ng ,
		Pili, R., et al. mice," Int. J. C	"Aden	ovirus- , Oct. 9	mediate , 1997,	d gene 73(2):2	transfer of 58-63. (	of fibroblas Abstract or	t grow lly)	th factor-1: angio	genesi	s and t	umorigenio	ity in r	ude
		Matsumoto, G Oncol, June 20	., et al. 001, 37	"Ang (4):369	iostatin 9-78. (A	gene th	erapy inh only)	ibits the g	rowth	of murine squamo	us cell	carcin	oma in viv	o," Ora	1
V.	٧	Riccioni, T., et angiogenesis i	al. "An vivo,	Adenov " <i>Gene</i>	irus-me <i>Ther</i> , J	diated v	wild-type 98, 5(6):7	p53 overe 47-54. (A	xpress bstract	ion inhibits endotl t only)	nelial c	ell diff	erentiation	in vitr	o and
EXAMI	NER	Swith D.	Pin	ile				DATE	CONS	IDERED /2	15/0	75			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Cukasia	a for form	1449B/PTO			Comple	te if I	Known		
			CLOSURE		Application No.		09/403,736		10/693
1		NT BY AP			Filing Date 10/26/1999				
	. 251122				Group Art Unit .1632 /633				
	(use	as many sheets	s as necessary)		Examiner Name S. Priebe				
Sheet	1		Of 1		Attorney Docket No. A2778A-US				
			U.S. PATI	ENT DO	CUMENTS				
Examiner Initials*		Document Number	Publication Date MM-DD-YYYY	Арр	Name of Patentee or plicant of Cited Document		es, Columns, Lines, verant Passages or Re Figures Appear		
					· · · · · · · · · · · · · · · · · · ·		•		
			······································					$\neg \neg$	
						<del> </del>	<u>-</u>		
		-	<u></u>	<del> </del>		1			}
		<u> </u>	FOREIGNIR	A CICHE INTOC. I	DOCUMENTO.	<u> </u>	- <del></del>		
	1	Foreign Patent	Publication Date	TENI	Name of Patentee or	Pag	es, Columns, Lines,	Where	
Examiner Initials*	Country	Document	MM-DD-YYYY	Арр	plicant in Cited Document	evant Passages or Re Figures Appear		l	
initials.	Code				<del> </del>		rigures Appear		1
									·
									]
	r	OTHER P	RIOR ART—NON	PATENT	LITERATURE DOCUMI	ENTS			]
Examiner Initials*	Inclu magazin	de name of the auth- e, journal, serial, syn	or (in CAPITAL LETT mposium, catalog, etc.)	TERS), title o ), date, page ( where publ	f the article (when appropriate) s), volume-issue number(s), pu ished	), title of iblisher,	the item (book, city and/or country	T <sup>1</sup>	
SOP	wild-type	e p53-mediated do	wnregulation of vas	al., titled "/	Antiangiogenic therapy for helial growth factor (VEGF p. 175. April 12, 199	) expres	ung cancer by		
									1
				<del> </del>				-	┨ .
				· · · · ·				1	
									]
									1
									-
									1
1								1	1
Examiner Signature	Sz	AT D. (?	nêhe		Pate /2/	05/0	95		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant is to place a check mark here if English language Translation is attached.

FORM (REV.		1449 (M	odified)						OMMERC RK OFFIC		ATTY. DO		٥. ا	APPLI /0/6 <del>29/40</del> 3	ICATIO 93,68 <del>3,73</del> 6	8 N N(	O.
		LIST C	F REF	EREN	CES C	CITED I	BY API	PLICAN	ΙΤ		APPLICAN	TV					
			(I le	e sever	al shee	ts if nec	essarv				Hong LI et	al.					
			(03	c sever	ar silce	ts ii nee	cssai y )				FILING DA	ATE	1	GROU	ЛР		
											October 26	1999		1633	•		
<u> </u>											1		l				
*EXAMINER	т	1					U.S.	PATE	IT DOCUM	IENT	<u>S</u>		1				2047
DITIAL		<b>}</b> -		DO	CUMENT N	UMBER	η	T	DATE	-	NAME			CLASS SUBCLASS		FILING DATE OF APPROPRIATE	
	<del> </del>	<b> </b>		<del> </del>	+	+				+	•		-				
				<b></b>	<del> </del>		<del>                                      </del>	-	<del> </del>	_							
		<b>!</b>		<del> </del>			ļ.:	<del></del>			<u>:</u>		+			<del> </del>	
	<del> </del>	<b> </b>			-		-	+					+				
				<del> </del>	- <del> </del>		+	1.		-		•	<del>                                     </del>	-	<del></del>	-	
				<del> </del>	╁	<del> </del>	<del> </del>	+					+				
						+	+			-		<del>i</del>				<del>                                     </del>	
					<del>                                     </del>	+		<del> </del>	-				-	+		-	<del></del>
					<del> </del>	+	<del>                                     </del>	<del>                                     </del>		+			-			├	
	l	L		l	1		OPE	I DAT	ENT DOC	I D (E)	NTTO.						
	Ι					<u>F</u>	OKEI	JIN PAI	ENT DOC	I	NIS		<u>····</u>	ı		TRANSL	ATION
				DOC	UMENT N	UMBER		¥****	DATE		COUNTRY CLA			ASS SUBCLASS		YES	NO
														<u> </u>			•
										<u> </u>		·					
<del></del>														L			
												·					
	·	<u> </u>							·								
													· <del>····</del>				
											te, Pertinent						
50P		GenB	ank e	ntry f	or hur	nan pl	asmir	ogen	and anno	tatio	ns from NC	BI web	page	, Acc.	No. F	007	47.
50P											n activator						
			A	cc.	No.	700	749									<del></del>	
EXAMI	NER	Sixt			neli				DATE	CONS	SIDERED	12/5/	05		· ·		
*EXAM:	INER: ance an	Initial if	referer nsidere	nce con d. Incl	siderec ude a c	l, wheth opy of t	er or no	ot citation	n is in confe ext commu	orman nicatio	ce with MPEI on to applicant	2 609; Dra	w line	throug	gh citati	on if r	not in

PTO/SB/08A (6-95)

Approved for use through 09/30/98, OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box

1449A/PTO

Sheet

+	
	!

U.S. Department of Commerce Patent and Trademark Office

19

## LIST OF PRIOR ART CITED BY

of

APPLICANT (use as many sheets as necessary)

1

Complete if Known							
Application Number	09/403,736 10/693,688						
Filing Date	26-October 1999						
First Named Inventor	Li et al.						
Group Art Unit	1633						
Examiner Name							
Attorney Docket Number	A2778A-US						

### **U.S. PATENT DOCUMENTS**

		· U.S. Patent	Document		Date of Publication	Pages, Columns, Lines, Where Relevant
Examiner nitials	Cite No.	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Passages or Rel vant Figures App ar
SDP	AA	4,650,764		Temin et al.	03-17-1987	
ſ	AB	4,797,368		Carter et al.	01-10-1989	
	AC	4,814,470		Colin et al.	03-21-1989	:
	AD.	4,857,653		Colin et al.	08-15-1989	
	AE	4,861,719		Miller	08-29-1989	
	AF	4,924,011		Denis et al.	05-08-1990	
	AG	4,980,289		Temin et al.	12-25-1990	
	AH	5,124,263		Temin et al.	06-23-1992	
	AI	5,139,941		Muzyczka et al.	08-18-1992	
	AJ	5,168,062		Stinski	12-01-1992	
V	AK	5,290,957		Correa et al.	03-01-1994	•

#### FOREIGN PATENT DOCUMENTS

Examin r Initials	Cite No.	For Office	eign Patent D	Oocument Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Rel vant Passages or Relevant Figures Appear	Т
	FA	EP-	185 573		Perricaudet et al.	<del>06-25-1986</del>		W
	F.B-	EP.	253 738		Golin et al.	07-17-1986		W
SDP	✓ FC	wo	89/07150		Bank et al.	08-10-1989	·	
1	∨ FD	CA	2012311		Beug et al.	03-15-1990		
	√ FE	wo	90/02806		Danos et al.	03-22-1990		
	FF	EP	453 242		Breakfield et al.	04-16-1990		<b>†</b>
	FG	wo	91/18088	·	Chatterjee et al.	11-28-1991		<del> </del>
	FH	wo	91/17976		Correa et al.	11-28-1991		<b>†</b>
V	FI	EP	178 220		Jacob et al.	02-01-1992		1

	·
EXAMINER SIGNATURE	DATE CONSIDERED
	DATE CONCIDENCED 13/-/02
SWA D. Creek	14/5/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Inf rmation Officer, Patent

Please type a plus sign (+) inside this box

1449A/PTO

Sheet

+

·19

U.S. Department of Commerce

Patent and Trademark Office

## LIST OF PRIOR ART CITED BY APPLICANT

of

(use as many sheets as necessary)

2

Compl	ete if Known
Application Number	09/403,736 /0/693,688
Filing Date	2 <del>6 October 1999</del>
First Named Inventor	Li et al.
Group Art Unit	. 1633
Examiner Name	
Attorney Docket Number	A2778A-US

### **U.S. PATENT DOCUMENTS**

		U.S. Patent	Document		Date of Publication	Pages, Columns, Lines, Where Relevant	
xaminer nitials	Cite No.	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
SDP	AL	5,292,921		Correa et al.	03-08-1994		
1	AM	5,385,839		Stinski .	01-31-1995	•	
	AN	5,399,346		Anderson et al.	03-21-1995		
	AO	5,438,072		Bobee et al.	08-01-1995		
	AP	5,459,127		Felgner et al.	10-17-1995		
	AQ	5,580,859		Felgner et al.	12-03-1996		
	AR	5,587,493		Bouchard et al.	12-24-1996		
	AS	5,589,466		Felgner et al.	12-31-1996		
V	AT	5,639,725		O'Reilly et al.	06-17-1997		

#### FOREIGN PATENT DOCUMENTS

		For	eign Patent D	ocument	,	Date of Publication	Pages, Columns, Lines, Where Relevant	
Examiner nitials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Т
50P	FJ	wo	92/05263		Inglis et al.	04-02-1992		Г
1	FK	wo	93/00928		Bastarty et al.	01-21-1993		N
$\neg \tau$	FL	wo	93/00929		Bastart et al.	01-21-1993		W
	FM	wo	93/09239		Srivastava	05-13-1993		
	FN	wo	93/15199	1 .	Fleer et al.	08-05-1993		M.
	FO	wo	94/12649		Gregory et al.	06-09-1994		
	FP	wo	94/21807	•	Inglis et al.	09-29-1994		1
1/	FQ	wo	94/26914		Haddada et al.	11-24-1994		N
V	FR	wo	94/28152		Imler et al.	12-08-1994		N

EXAMINER SIGNATURE	DATE CONSIDERED	/ / -	
- Carlo	Ditte Gotto:DEITED	12/5/15	
John Dine		12/3/03	·

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n t in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent

PTO/SB/08A (6-95)

Please ty	pe a pl	us sign	(+) inside	this box	Г	+)	Patent and Trade	Approved for emark Office	use through: U.S. DEF	ah 09/30/98	10/36/06Д (0 3, ÓMB 0651- Г ОГ СОММЕ	.กกร 1
1449A/PTO U.S. Department of Commerce					Complete if Known							
				Patent an	d Trade	mark Office	Application Numl	her	004400	726	18/107	-
ı	IST	OF D	RIOR A	APT CIT	ren e	~	Filing Date		09/403		10/693,6	,58
·	_101		APPLIC		בט פ	1	First Named Inve		<del></del>	ober 19	99	
	lus	-	any sheets		(vness		Group Art Unit	ntor	Li et	aı.	• • •	
	,00		arry critecia	3 40 11000	,						163	3
			<del>~</del>	<del></del>	<del></del>	40	Examiner Name		ļ			
Shee	t		3	of		19	Attorney Docket	Number	<u> </u>	A2778.A-	us	
•						U.S. PATEN	T DOCUMENTS			•	••	
		U	.S. Patent	Documen	t						es, Columns,	
Examiner nitials	Cite No.	Numt	oer		d Code known)	4	tentee or Applicant ed Document		Publication Document YYYY	Passag	Mhere Releva ges or Rel val ures Appear	nt
		1		• 1			•	T		<del>                                     </del>		<u> </u>
						<u> </u>				ļ	<del></del>	
									_			
		1			·			T		· -	<del></del> -	
		1		T I	<del></del>							
										•		
									•			
											<del></del>	
							· · · · · · · · · · · · · · · · · · ·					
		<del></del>		···········	FO	REIGN PATI	ENT DOCUMEN	TS		<del>. t </del>		
		For	eign Paten	t Docume				Date of Pu	blication		Columns, ere Relevant	
Examiner nitials	Cite No.	Office	Number		d Code (nown)		entee or Applicant d Document	of Cited Do	cument	Passages	or Relevant s Appear	т
50P	FS	wo	94/28938	}	1	Wilson et al.		12-22-1	1994	•		
7	FT	wo	95/02697			Perricaudet e	t al.	01-26-1	1995			N
	FU	wo	95/07358			Dougherty et	al.	03-16-1	1995			ا
	FV	wo	95/18863			Behr et al.		07-13-1	995	•		N
	FW	wo	95/21931	·		Bazile et al.	7/7 ' 7/1	08-17-1	995			N
	FX	wo	95/28494			Overell et al.		10-26-1	995	•		
	FY	wo	95/29242	• •		O'Reilly et al.		11-02-1	995			1
1.	F7	FP	488 528		1	l ehkowski et	al	11-20-1	995			1

EXAMINER SIGNATURE Soft D. Cricke DATE CONSIDERED 12/5/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

01-18-1996

Bujard et al.

wo

96/01313

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not irreduced and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two etter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede he serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO tandard ST.1 if possible. Applicant is to place a check mark here if English language Translation is attached.

turden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual ase. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patern C

PTO/SB/08A (6-95)

Approved for use through 09/30/98, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a	plus :	sign (	(+)	inside	this	box
---------------	--------	--------	-----	--------	------	-----

1449A/PTO

Sheet

+	1
	Į.

19

U.S. Department of Commerce

Patent and Trademark Office
LIST OF PRIOR ART CITED BY

of

APPLICANT (use as many sheets as necessary)

4

Complete if Known						
Application Number	09/403,736 10/693 688					
Filing Date	26 October 1999					
First Named Inventor	Li et al.					
Group Art Unit	1633					
Examiner Name						
Attorney Docket Number	A2778-A-US					

### **U.S. PATENT DOCUMENTS**

Examiner nitials			Cite No.	U.S. Patent	Document Kind Code	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
nitiais	NO.	Number	(II KIIOWII)	of Cited Document	MM-DD-YYYY ·	Figures Appear		
		<del> </del>						
		<del></del>	<del> </del> -					
					ļ			

## FOREIGN PATENT DOCUMENTS

		For	eign Patent (	Document		Date of Publication	Pages, Columns, Lines, Where Relevant	
Examiner Initials	Cit No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Т.
508	GB	wo	96/01815		Authelin et al.	01-25-1996		W
	66-	FR-	2726285		Yeh et al.	05-03-1998		A
SDR	GD	wo	96/17823		Byk et al.	06-13-1996		N
	GE	wo	96/22378		Dedieu et al.	07-25-1996		N
	GF	WO	96/25508		Byk et al.	08-22-1996		N
	GG	wo	97/04092		Conseiller et al.	02-06-1997		N
V	GH	wo	97/15666	•	O'Řeilly et al.	05-01-1997		
		1 1						

EXAMINER SIGNATURE	DATE CONSIDERED 1-1-C
Sest D. Inche	12/5/05
	, – , – , – , – , – , – , – , – , – , –

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. See attached kinds of U.S. Patent Documents. Enter Office that issued the document, by the two etter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede he serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO standard ST.1 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent

Please	hina	a pluc	cian	4	incido	thic	hoy
Please	type	a pius	Sign	(Ŧ)	1112106	นแจ	DOX

1	+

1449A/PTO			nent of Commerce Trademark Office	Сотр	lete if Known
		Patent and	Trademark Office	Application Number	09/403,736 10/693.688
LIST	OF PRIOR	ART CITE	D BY	Filing Date	<del>26 October 1999</del>
	APPLI			First Named Inventor	Li et al.
(u	se as many she	ets as necessa	ary)	Group Art Unit	/633
				Examiner Name	
Sheet	5	of	19	Attorney Docket Number	A2778 A_IIC

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	t i b ty the state of the state	
Estreicher et al., The Receptor for Urokinase Type Plasminogen Activator Polarizes Expression of the P the Leading Edge of Migrating Monocytes and Promotes Degradation of Enzyme Inhibitor Complexes, of Cell Biology 111, 783-792 (1990)		Estreicher et al., The Receptor for Urokinase Type Plasminogen Activator Polarizes Expression of the Protease to the Leading Edge of Migrating Monocytes and Promotes Degradation of Enzyme Inhibitor Complexes, Journal of Cell Biology 111, 783-792 (1990)	
	₽B	Pepper et al., Chondrocytes Inhibit Endothelial Sprout Formation In Vitro: Evidence for Involvement of a Transforming Growth Factor-Beta, Journal of Cellular Physiology 146, 170-179 (1991)	
	PC	Ploug et al., Cellular Receptor for Urokinase Plasminogen Activator, The Journal of Biological Chemistry 266(3), 1926-1933 (1991)	
	PD	Ellis et al., Plasminogen Activation by Receptor-bound Urokinase, The Journal of Biological Chemistry 266(19), 12752-12758 (1991)	
	PE	Wei et al., Identification of the Urokinase Receptor as an Adhesion Receptor for Vitronectin, The Journal of Biological Chemistry 269(51), 32380-32388 (1994)	
	PF	Appella et al., The Receptor-binding Sequence of Urokinase: A Biological Function for the Growth-Factor Module of Proteases, The Journal of Biological Chemistry 262(10), 4437-4440 (1987)	
	PG	Cao et al., Kringle Domains of Human Angiostatin, The Journal of Biological Chemistry 271(46), 29461-29467 (1996)	
	PH	Imren et al., Overexpression of Tissue Inhibitor of Metalloproteinases-2 by Retroviral-mediated Gene Transfer in Vivo Inhibits Tumor Growth and Invasion, Cancer Research 56, 2891-2895 (1996)	

EXAMINER SIGNATURE	DATE CONSIDERED	7 - 1	
EXAMINER SIGNATURE STATE ). ( Justie	DITTE GONOLDEINED	12 12115	
8000 J. 600004		12/1/03	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

3urden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual ase. Any comments n the amount of time you are required to complete this form should be sent to the Chief Information Officer,

Please type a plus sign (+) inside this box

1449A/PTO

Sheet

		J ————
nent	of	Commerce

19

U.S. Departn Patent and Trademark Office

## LIST OF PRIOR ART CITED BY **APPLICANT**

of

(use as many sheets as necessary)

6

Complete if Known					
Application Number	09/403,736 /0/693 688	<u>-</u>			
Filing Date	26 October 1999				
First Named Inventor	Li et al.	_			
Group Art Unit	1633	_			
Examiner Name					
Attorney Docket Number	A2778 A-US	_			

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner nitials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	Т
SDP	PI	Shapiro et al., Induction of Primary Cutaneous Melanocytic Neoplasms in Urokinase-Type Plasminogen Activator (uPA)-deficient and Wild-Type Mice: Cellular Blue Nevi Invade but Do Not Progress to Malignant Melanoma in uPA-deficient Animals, Cancer Research 56, 3597-3604 (1996)	
		Skladanowski et al., Expression of Wild-Type p53 Increases Etopside Cytotoxicity in M1 Myeloid Leukernia Cells by Facilitated G2 to M Transtition: Implication for Gene Therapy, Cancer Research 57, 818-823 (1997)	
	PK	Sim et al., A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer, Cancer Research 57, 1329-1334 (1997)	
	PL	Liotta et al., Quantitative Relationships of Intravascular Tumor Cells, Tumor Vessels, and Pulmonary Metastases folling Tumor Implantation, Cancer Research 34, 997-1004 (1974)	
	PM	Hori et al., Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibodies against Human Basic Fibroblast Growth Factor, Cancer Research 51, 6180-6184 (1991)	
	PN	Min et al., Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor in Syngeneic Mice, Cancer Research 56, 2428-2433 (1996)	
	PO	Wei et al., Regulation of Integrin Function by the Urokinase Receptor, Science 273, 1551-1555 (1996)	
V	PP	Graeber et al., Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours, Natur 379, 88-91 (1996)	

EXAMINER SIGNATURE	1 xx 0 x1	DATE CONSIDERED	
	Scott D. (Zniche	12/3/05	
	0.6700	1-/ 7-/ 0-	

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not a conformance and not considered. Include copy of this form with next communication to applicant.

Inique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

urden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual ase. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

Approved for use through 09/30/98, OMB 0651-0031

Please type a plus sign (+) inside this box

+	

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449A/PTO			ent of Commerce					
	Patent and Trademark Office			Application Number	09/403,736 10/693,688			
LIST	OF PRIOR	ART CITE	D BY	Filing Date	26-October 1999			
•	APPLI	CANT		First Named Inventor	Li et al.			
(u	se as many she	ets as necessa	ry)	Group Art Unit	1633			
				Examiner Name				
Sheet	7	of	19	Attorney Docket Number	<del>42778</del>			

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	Т
5DP	Bacharach et al., In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role regulating physiological angiogenesis, Cell-Biology 89, 2632-2636 (1989) Proc. Natl. Acad. Sci., USA 89: 10686-10690 (1992)		
	PR	He et al., Tissue cooperation in a proteolytic cascade activating human interstitial collagenase, Proc. Natl. Acad. Sci. 86, 2632–2636 (1989)	
	PS	Crowley et al., Prevention of metastasis by inhibition of the urokinase receptor, Proc. Natl. Acad. Sci. 90, 5021-5025 (1993)	
+	PT	Davis et al., Monoclonal antibodies to mitotic cells, Proc. Natl. Acad. Sci. 80, 2926-2930 (1983)	
	PU	Gupta et al., A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4, Proc. Natl. Acad. Sci 92, 7799-7803 (1995)	
	PV	Mignatti et al., Biology & Biochemistry of Proteinases in Tumor Invasion, Physiological Reviews 73(1), 161-195 (1993)	
	PW	Pyke et al., Urokinase-type Plasminogen Activator is Expressed in Stromal Cells and Its Receptor in Cancer Cells and Its Receptor in Cancer Cells at Invasive Foci in Human Colon Adenocarcinomas, American Journal of Pathology 138(5), 1059-1067 (1991)	
	PX.	Magdolen et al., Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator, Eur J. Biochem 237, 743-751 (1996)	
	L	<u> </u>	

·				
EXAMINER SIGNATURE	C V/\ O \	/ DATE CON	ISIDERED	1.1
	Sciett (). ( ne	h	/2./	1 <i>710</i> 5
	0-0,000			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

308

Approved for use through 09/30/98, OMB 0651-0031

Please	type a	plus	sian	(+)	inside	this	box
110030	type a	Pius	3.9.1	٧.,	111314		

-	+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449A/PTO		•	ent of Commerce	Compl	ete if Known	
		Patent and a	rademark Office	Application Number	09/403,736	10/693,688
LIST	OF PRIOR	ART CITE	D BY	Filing Date	26 October 19	
	APPLI			First Named Inventor	Li et al.	
(u:	se as many she	ets as necessa	ry)	Group Art Unit	1633	
				Examiner Name		
Sheet	8	of	19	Attorney Docket Number	A2778A-US	

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	Т
SDP	У РҮ	Schmitt et al., Tumor-associated Proteases, Fibrinolysis 6(4), 3-26 (1992)	
	PZ	Stratford-Perricaude et al., Widespread Long-term Gene Transfer to Mouse Skeletal Muscles and Heart, J. Clin. Invest. 90, 626-630 (1992)	
	QA	Weidner et al., Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma; The New England Journal of Medicine 324(1), 1-8 (1991)	
	QB	Hanahan et al., Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis, Cell 86, 353-364 (1996)	
	QC	Wickham et al., Integrins avB3 and avB5 Promote Adenovirus Internalization but Not Virus Attachment, Cell 73, 309-319 (1993).	
	QD	Brooks et al., Integrin avB3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, Cell 79, 1157-1164 (1994)	
	QE	O'Reilly et al., Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth, Cell 88, 277-285 (1997)	
V	QF	Dong et al., Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma, Cell 88, 801-810 (1997)	

EXAMINER SIGNATURE	0:45 () 5/	DATE CONSIDERED	101-	
	XXVIII all	D	17 / 7/05	
	0019 0-6 1000		1-11	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

Please ty	ре а	plus	sign	(+)	inside	this	box
-----------	------	------	------	-----	--------	------	-----

1449A/PTO

Sheet

_
[
T 1

U.S. Department of Commerce

Complete & Kramm

	1	Patent and Trademar	k Office
LIST	OF PRIOR A	RT CITED BY	

APPLICANT (use as many sheets as necessary)

of

9

Compl	ete if Known
Application Number	09/403,736 10/693,688
Filing Date	26-October 1999
First Named Inventor	Li et al.
Group Art Unit	1633
Examiner Name	
Attorney Docket Number	∆2778 A <del>. He</del>

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner nitials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	Т
SDP	ر QG	King et al., Mitosis in Transition, Cell 79, 563-571 (1994)	
	V∕ QH	Yeh et al., Advances in adenoviral vectors: from genetic engineering to their biology, FASEB 11, 615-623 (1997)	
	.V QI	Folkman, What Is the Evidence That Tumors Are Angiogenesis Dependent?, Journal of the National Cancer Institute 82(1), 4-6 (1990)	
	ГÒ	Mirshahi et al., Evaluation of the Inhibition by Heparin and Hirudin of Coagulation Activation During r-tPA-Induced Thrombolysis, Blood, 74(3) 1025-1030 (1989)	
	.J QK	Plate et al., Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature 359, 845-848 (1992)	
	√ QL	Roth et al., Gene Therapy for Cancer: What Have We Done and Where Are We Going?, Journal of the National Cancer Institute 89(1), 21-39 (1997)	-
	V QM	Clapp et al., The 16-Kilodalton N-Terminal Fragment of Human Prolactin Is a Potent Inhibitor of Angiogenesis, Endocrinology 133(3), 1292-1299 (1993)	-
V	QN	Kim et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature 362, 841-844 (1993)	

			<u> </u>
EXAMINER SIGNATURE	0 -1 \ () \ \ \	DATE CONSIDERED 12/0//	
	South A (/: il	12/6/1/2	
	July D. [ new	, 7 8/63	
SAAN ATS TITTE TO A SAA SAA C			

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not a conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

urden Hour Statement: This form is estimated to take .2 hours to complet. Time will vary depending upon the needs of the individual ase. Any comments on the amount of time you are required t complet this form should be sent to th Chief Information Officer,

Please type a plus sign (+) inside this box

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449A/PTO			nent of Commerce Trademark Office	Complete if Known		
		Patent and	rademark Office	Application Number	09/403,736 10/693,688	
LIST	OF PRIOR	ART CITE	D BY	Filing Date	26 October 1999	
	APPLI			First Named Inventor	Li et al.	
(us	e as many shee	ets as necessa	ny) .	Group Art Unit	1633	
				Examiner Name		
Sheet	10	of	19	Attorney Docket Number	-A2778 A-US	

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	Т
50P	Q0	Hamada et al., Separable groth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis, Br. J. Cancer 66, 349-354 (1992)	
	QP	Trochon et al., Evidence of Involvement of CD44 In Endothelial Cell Proliferation, Migration and Angiogenesis In Vivo, Int. J. Cancer 66, 664-668 (1996)	
	i/ QQ	Fan et al., Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy, TiPS 16, 57-66 (1995)	
	√ QR	Rifkin et al., Growth factor control of extracellular proteolysis, Cell Differentiation & Development 32, 313-318 (1990)	
	√ QS	Lu et al., Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells, FEBS Letters 380, 21-24 (1996)	
	QT	Kobayashi et al., Inhibition of Metastasis Of Lewis Lung Carcinoma By A Synthetic Peptide Within Grown Factor-Like Domain Of Urokinase In The Experimental and Spontaneous Metastasis Model, Int. J. Cancer 57, 727-733 (1994)	
	√ QU	Lu et al., Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin, FEBS Letters 356, 56-59 (1994)	
$\mathbb{V}$	QV	Holmgren et al., Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression, Nature Medicine 1(2), 149-153 (1995)	

		<u> </u>	•	
EXAMINER SIGNATURE	0 11 -1	1 DATE CONSIDERED		
	South D. I well	DATE CONCIDENCE	17/9/09	
	DURUI O. LIVEUT		12/1/07	
23444441222		<del></del>	<del></del>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

A2778 A-US

Please	type	а	plus	sign	(+)	inside	this	box
--------	------	---	------	------	-----	--------	------	-----

1449A/PTO

+	

Patent and Trademark Office

U.S. Department of Commerce

Complete if Known

Application Number

Piling Date

First Named Inventor

Group Art Unit

Complete if Known

Application Number

Application Numbe

LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 19 Attorney Docket Number

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	т
SDP	√QW	Graham et al., Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5, J. Gen. Virol. 36, 59-72 (1977)	
	QX	Hayes et al., Carbohydrate of the Human Plasminogen Variants, The Journal of Biological Chemistry 254(18), 8772-8776 (1979)	
	QY	Roldan et al., Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis, The EMBO Journal 9(2), 467-474 (1990)	
	v QZ	Hirt, Selective Extraction of Polyoma DNA from Infected Mouse Cell Cultures, J. Mol. Biol. 26, 365-369 (1967)	
	∨ RA	Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease, Nature Medicine 1(1), 27-31 (1995)	
	√ RB	Belin et al., Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator, Eur. J. Biochem 148, 225-232 (1985)	
	RC	Naldini et al., Extracellular proteolytic cleavage by urolinase is required for activation of hepatocyte growth factor/scatter factor, The EMBO Journal 11(13), 4825-4833 (1992)	
N	√ RD	O'Reilly et al., Angiostatin induces and sustains dormancy of human primary tumors in mice, Nature Medicine 2(6), 689-692 (1996)	

EXAMINER SIGNATURE	O WX		I DATE CONSIDERED	10/0/-	
	Scott D.	nele		12/8/05	
	0001			, ,	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not n conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual ase. Any comments on the amount of time you are required to complete this form should be sent t the Chief Information Officer,

Approved for use through 09/30/98, OMB 0651-0031

Please typ	e a plu	s sign (+	) inside	this box	C
------------	---------	-----------	----------	----------	---

- 1	+	

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449A/PTO		•	ent of Commerce	Goinpiete ii ranonni			
:		Patent and	rademark Office	Application Number	09/403,736 /0/693,688		
LIST	OF PRIOR	ART CITE	D BY	Filing Date	26 October 1999		
	APPLI			First Named Inventor	Li et al.		
(us	e as many shee	ets as necessa	ry)	Group Art Unit	1633		
				Examiner Name			
Sheet	12	of	19	Attorney Docket Number	A2778A=US		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	т
SDP	RE	Dvorak et al., Iidentification and Characterization of the Blood Vessels of Solid Tumors That Are Leaky to Circulating Macromolecules, American Journal of Pathology 133(1), 95-109 (1988)	
	RF	Readhead et al., Expression of a Myelin Basic Protein Gene in Transgenic Shiverer Mice: Correction of the Dysmyelinating Phenotype, Cell, 48, 703-712 (1987)	
	<b>√</b> RG	Kollias et al., Regulated Expression of Human A Gamma, Beta, and Hybrid Gamma Beta-Globin Genes in Trasgenic Mice: Manipulation of the Developmental Expression Patterns, Cell 46, 89-94, (1986)	
	RH	Leder et al., Consequences of Widespread Deregulation of the c-myc Gene in Transgenic Mice: Multiple Neoplasms and Normal Development, Cell 45, 485-495 (1986)	
	γ RI	Yamamoto et al., Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus, Cell 22, 787-797 (1980)	
	/ RJ	Mann et al., Construction of a Retrovirus Packaging Mutant and Its Use to Produce Helper-Free Defective Retrovirus, Cell 33, 153-159 (1983)	
	V RK	Swift et al., Tissue-Specific Expression of the Rat Pancreatic Elastase I Gene in Transgenic Mice, Cell 38, 639-646 (1984)	
V	i∕ RL	Grosschedl et al., Introduction of a Micro Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid Cells and Synthesis of Functional Antibody, Cell 38, 647-658 (1984)	

EXAMINER SIGNATURE	( > \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	DATE CONSIDERED 12/6/05	
	Stott D. Criel	~ 12/8/05	
	0001 2.600		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not n conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is t place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

				_				
Please	tvoe	а	plus	sian	(+)	inside	this	box
	.,, ,	-	F		` '		•	

1449A/PTO

Sheet

+	

U.S. Department of Commerce
Patent and Trademark Office

# LIST OF PRIOR ART CITED BY APPLICANT

of

(use as many sheets as necessary)

13

Compl	ete if Known
Application Number	09/403,736 10/693,688
Filing Date	26 <del>-October 19</del> 99
First Named Inventor	Li et al.
Group Art Unit	1633
Examiner Name	- / <del>* / </del>
Attorney Docket Number	A2778 A-US

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	т
5DP			
	RN	Kuo et al., Efficient Gene Transfer Into Primary Murine Lymphocytes Obviating the Need for Drug Selection, Blood 82(3), 845-852 (1993)	
	RO .	Machy et al., Gene transfer from targeted liposomes to specific lymphoid cells by electroporation, Proc. Natl. Acad. Sci. 85, 8027-8031 (1988)	<del>  -</del>
	√ RP	Felgner et al., Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. 84, 7413-7417 (1987)	
	RQ	Bender et al., Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region, Journal of Virology 1639-1646 (1987)	
	√ RR	Ulmer et al., Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein, Science 259, 1745-1749 (1993)	
	RS	Le Gal La Salle et al., An Adenovirus Vector For Gene Transfer into Neurons and Glia in the Brain, Science 259, 988-990 (1993)	
V	;/ RT	Samulski et al., A Recombinant Plasmid from Which an Infectious Adeno-Associated Virus Genome Can Be Excised In Vitro and Its use To Study Viral Replication, Journal of Virology 61(10), 3096-3101 (1987)	

EXAMINER SIGNATURE	DATE CONSIDERED	1-1.00	,
376/////	O	17/8/15	•
our D. Crieve		10/0/0-	<u> </u>
VANISHED I SELECT CO. 11 1 1 1 1			

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n to conformance and not considered. Include copy of this form with next communication to applicant.

Juique citation designation number. Applicant is to place a check mark here if English language Translation is attach d.

urden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual ase. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

Please	type	а	plus	sign	(+)	inside	this	box
110030	1) PC	u	pius	Jigii	1,1	1113106	11113	

+	1

1449A/PTO U.S. Department of Commerce		Complete if Known			
Patent and Trademark Office				Application Number	09/403,736 10/693,688
LIST OF PRIOR ART CITED BY				Filing Date	26 October 1999
	APPLICANT (use as many sheets as necessary)			First Named Inventor	Li et al.
(0				Group Art Unit	1633
				Examiner Name	
Sheet	14	of	19	Attorney Docket Number	A2778_A=US

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	τ.
5DP	RM	Lebkowski et al., Adeno-Associated Virus: a Vector system for Efficient Introduction and Integration of DNA into a Variety of Mammalian Cell Types, Molecular & Cellular Biology 8(10), 3988-3996 (1988)	
	RN	Alexander et al., Expression of the c-myc Oncogene under Control of an Immunoglobulin Enhancer in Eu-myc Transgenic Mice, Molecular & Cellular Biology 7(4), 1436-1444 (1987)	
	RO	Krumlauf et al., Developmental Regulation of alpha-Fetoprotein Genes in Transgenic Mice, Molecular & Cellular Biology 5(7), 1639-1648 (1985)	
	√ RP	Hammer et al., Diversity of Alpha-Fetoprotein Gene Expression in Mice Is Generated by a Combination of Separate Enhancer Elements, Science 235, 53-58 (1987)	
	√ RQ	Mason et al., The Hypogonadal Mouse: Reproductive Functions Restored by Gene Therapy, Science 234, 1372-1378 (1986)	
	√ RR	Williams et al., Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles, Proc. Natl. Acad. Sci. 88, 2726-2730 (1991)	
·	√ RS	DeBoer et al., The tac promoter: A functional hybrid derived from the trp and lac promoters, Proc. Natl. Acad. Sci. 80, 21-25 (1983)	
V	√ RT	Villa-Komaroff et al., A bacterial clone synthesizing proinsulin, Proc. Natl. Acad. Sci. 75(8), 3727-3731 (1978)	

EXAMINER SIGNATURE	Scott D. Prick.	DATE CONSIDERED 12/8/05
XAMINER: Initial if reference	considered, whether or not citation	on is in conformance with MPEP 609. Draw line through citation if not

n conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

furden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual ase. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

1449A/PTO

Sheet

+

erce

U.S. Department of Commerce Patent and Trademark Office

## LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)

of

15

. Comp	lete if Known
Application Number	09/403,736 /0/693,688
Filing Date	26 October 1999
First Named Inventor	Li et al.
Group Art Unit	1633
Examiner Name	
Attorney Docket Number	A2778 A-119

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner nitials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	т
SDP	RU	Wagner et al., Nucleotide sequence of the thymidine kinase gene or herpes simplex virus type 1, Proc. Natl. Acad. Sci. 78(3), 1441-1445 (1981)	
	RV	Hutchison et al., A complete library of point substitution mutations in the glucocorticoid response element of mouse mammary tumor virus, Proc. Natl. Acad. Sci. 83, 710-714 (1986)	
	RW	Wu et al., Receptor-mediated Gene Delivery and Expression in Vivo, Journal of Biological Chemistry 263(29), 14621-14624 (1988)	
	RX	Wilson et al., Hepatocyte-directed Gene Transfer in Vivo Leads to Transient Improvement of Hypercholesterolemia in Low Density Lipoprotein Receptor-deficient Rabbits, Journal of Biological Chemistry 267(2), 963-967 (1992)	
	RY	Wu et al., Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System, Journal of Biological Chemistry 262(10), 4429-4432 (1987)	
	RZ	Benoist et al., In vivo sequence requirements of the SV40 early promoter region, Nature 290, 304-310 (1981)	
	SA	Brinster et al., Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs, Nature 296, 39-42 (1982)	
V	SB	Shani, Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice, Nature 314, 283-286 (1985)	

EXAMINER SIGNATURE Shott D. Crick	DATE CONSIDERED	12/9/05.	
000000		12/1/00	

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n t conformance and not considered. Include copy of this form with next communication to applicant.

Inique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

urden H ur Statement. This f rm is estimated to tak .2 hours to complete. Time will vary depending upon the needs of the individual ise. Any comments on the amount of time you are required to complet this form should be sent to the Chief Information Officer,

Please	type	a plus	sign	(+)	inside	this	box
--------	------	--------	------	-----	--------	------	-----

+	

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449A/PTO			ment of Commerce Trademark Office	Complete if Known		
				Application Number	09/403,736 10/693,688	
LIST	OF PRIOR			Filing Date	26-October 1999	
	APPLI			First Named Inventor	Li et al.	
(us	se as many she	ets as necess	ary)	Group Art Unit	1633	
				Examiner Name		
Sheet	16	of	19	Attorney Docket Number	A2778 A-US	

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of ' the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	T.
5D(	sc	Hanahan, Heritable formation of pancreatice Beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes, Nature 315, 115-122 (1985)	
	SD	Magram et al., Developmental regulation of a cloned adult Beta-globin gene in transgenic mice, Nature 315, 338-340 (1985)	
	SE	Gilbert et al., Useful Proteins from Recombinant Bacteria, Scientific American 242(4), 74-94 (1980)	
	SF	Kaplitt et al., Expression of a Functional Foreign Gene in Adult Mammalian Brain following in Vivo Transfer via a Herpes Simplex Virus Type 1 Defective Viral Vector, Molecular & Cellular Neurosciences 2, 320-330 (1991)	
	SG	Samulski et al., Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression, Journal of Virology 63(9), 3822-3828 (1989)	
	sh	Beard et al., Transcription Mapping of Mouse Adenovirus Type 1 Early Region 3, Virology 175, 81-90 (1990)	
1 1	SI	Levrero et al., Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo,  Gene 101, 195-202 (1991)	
N/I	SJ	Graham, Covalently closed circles of humand adenovirus DNA are infectious, The EMBO Journal 3(12), 2917-2922 (1984)	

EV ANDROGEN CONTRACTOR OF THE			
EXAMINER SIGNATURE	DATE CONSIDERED	13/9/06	
groad D. Vrive		12/9/03	
EVANIANTED I WELL	<u> </u>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if n t n conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending up in the needs of the individual ase. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

Please	type.a	plus	sign	(+)	inside	this	box
--------	--------	------	------	-----	--------	------	-----

LIST OF PRIOR

1449A/PTO

Sheet

_
_

)		U.S. Departm	ent of Commerce	Compl	lete if Known
		Patent and T	rademark Office	Application Number	09/403,736 /0/693,688
ST C	F PRIOR	ART CITE	D BY	Filing Date	26 <del>-October 199</del> 9
APPLICANT (use as many sheets as necessary)				First Named Inventor	Li et al.
				Group Art Unit	/633
				Examiner Name	
	17	of	19	Attorney Docket Number	A07704-UC

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	Т
SDP	√ SK	Pinkert et al., An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice, Genes & Development 1, 268-276 (1987)	-
	SL	Adams et al., The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice, Nature 318, 533-538 (1985)	
	√ SM	Kelsey et al., Species- and tissue-specific expression of human alpha1-antitrypsin in transgenic mice, Genes & Development 1, 161-171 (1987)	
	SN	Johnson et al., Inhibition of Angiogenesis by Tissue Inhibitor of Metalloproteinase, Journal of Cellular Physiology 160, 194-202 (1994)	
	so	Wilhelm et al., Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA) Inhibition of proliferation and invasion of human ovarian cancer cells, FEBS Letters 337, 131-134 (1994)	
	SP	Hutchinson et al., Mutagenesis at a Specific Position in a DNA Sequence, The Journal of Biological Chemistry 253(18), 6551-6560 (1978)	
	SQ SQ	Oliphant et al., Cloning of random-sequence oligodeoxynucleotides, Gene 44, 177-183 (1986)	
V	SR	Bernstein et al., Gene Transfer with Retrovirus Vectors, Genetic Engineering 7, 235-261 (1985)	

EXAMINER SIGNATURE	1 . 12 () 1/	DATE CONSIDERED	/ / -	
	Sutt D. Crube	DITTE CONCIDENCE	17/9/05	
	0000	· ·	16/1/4	
CVALABLED 1 111 116 6				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time y u are required to complete this form should be sent to the Chief Information Officer,

Please type a plus sign (+) inside this	box	
---	-----	--

			<u>—</u> .		
1449A/PTO			ment of Commerce	Comp	lete if Known
		Patent and	Trademark Office	Application Number	09/403,736 /0/693,688
LIST OF PRIOR ART CITED BY  APPLICANT  (use as many sheets as necessary)				Filing Date	2 <del>6 October</del> 1999
				First Named Inventor	Li et al.
				Group Art Unit	1633
				Examiner Name	
Sheet	18	of	19	Attorney Docket Number	A2779 * NC/

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner nitials	Cit No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	Т
SUP	SS	McCormick, Human Gene Therapy: The First Round, Bio/Technology 3(8), 689-693 (1985)	
	ST	Miller et al., Improved Retroviral Vectors for Gene Transfer and Expression, BioTechniques 7(9), 980-990 (1989)	-
	SU	Felgner et al., Cationic liposome-mediated transfection, Nature 337, 387-388 (1989)	
	√ sv	Curiel et al., High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes, Human Gene Therapy 3, 147-154 (1992)	-
	SW	Zoller et al., Laboratory Methods – Oligonucleotide-Directed Mutagenesis: A Simple Method Using Two Oligonucleotide Primers and a Single-Stranded DNA Template, DNA 3(6), 479-488 (1984)	
	✓ SX	MacDonald, Expression of the Pancreatic Elastase I Gene in Transgenic Mice, Hepatology 7(1), 42S-51S (1987)	
	SY	O'Reilly et al., Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma, Cell 79, 315-328 (1994)	
	SZ	Dedieu et al., Long-Term Gene Delivery into the Livers of Immunocompetent Mice with E1/E4-Defective Adenovirus, Journal of Virology 71(6), 4626-4637 (1997)	

EXAMINER SIGNATURE	Svott D. Priche	DATE CONSIDERED	12/12/05	<del></del>
XAMINER: Initial if refere	nce considered whether or no	t citation is in conformance with I	MPED 600 Drown line through sites	

conformance and not considered. Include copy of this form with next communication to applicant.

Inique citation designation number. Applicant is to place a check mark her if English language Translation is attached.

arden Hour Statement: This form is estimated to take .2 hours to complet . Time will vary depending upon the needs of the individual se. Any comm nts on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

PTO/SB/08A (6-95)

Approved for use through 09/30/98, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus s	ign (+) inside this box
A LIGA (DTO	

19

Sheet

A/PTO U.S. Department of Commerce

of

Patent and Trademark Office

19

## LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)

Compl	lete if Known
Application Number	09/403,736 10/693,688
Filing Date	26-00tober 1999
First Named Inventor	Li et al.
Group Art Unit	1633
Examiner Name	
Attorney Docket Number	A9778-4=119

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner nitials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	т
SDP	TA	Mirshahi et al., A monoclonal antibody directed against an epitope in the NH2-terminal region of native human plasminogen induced a modification of its functional properties, Fibrinolysis & Proteolysis 11(3), 155-163 (1997)	
	тв	Farrell, Recombinant Herpesviruses Lacking Gene For Glycoprotein L, RD#37105A by Cantab Pharmaceuticals Res. Ltd (1995)	·
	<del></del>		

TO A STREET OF THE STREET		_ <u>-'</u> -		
EXAMINER SIGNATUR	(E 0 44) 17:1	DATE CONSIDERE	D i i	
		DATE GOLIOIDENE	12/4/05	
	July D. V new		12/9/05	
CAMINIED, Initial if and				

CAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

nique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

irden Hour Statement: This form is estimated to tak .2 hours to complete. Time will vary dep inding upon the needs of the individual se. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer,

## Notice of References Cited

Application/Control No. QQ1403,736 10/693,688

Applicant(s)/Patent Under Reexamination LI ET AL.

Examiner

U.S. PATENT DOCUMENTS

Eleanor Sorbello

Art Unit 1633

Page 1 of 1

	*	Document Number Country Code-Number-Kind Code	Date MM-YYYY
//			

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Class	fication
	A	US-6,251,433	06-2001	Zuckermann et al	424	486
	В	US-5,652,095	07-1997	Taniguchi et al	435	6
	С	US-		·		
	D	US-				
	Ε	US-				
	F	US-				
	G	US-				<b> </b>
	Н	US-				
	ı	US-				
	J	US-				
	К	US				
	٦	US-				-
	М	US-				<b>-</b>

## FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	s					
	т			:	· · · · · · · · · · · · · · · · · · ·	

## **NON-PATENT DOCUMENTS**

	*	<b> </b>	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
P		U	Wilson, Vehicles for gene therapy, 1993, NAUTRE, Vol. 365, pp. 691-692
		٧	
		w	
		x	

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY formal are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. UT-2001)

Notice of References Cited

Part of Paper No. 19

Fro-1449

10/693,688

## Notice of References Cited

09/403,736

Art Unit /633

Applicant(s)/Patent Under Reexam Li et al.

Examiner

Scott D. Priebe, Ph.D.

1632

Page 1 of 1

#### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Clas	ssification <sup>2</sup>
	A	6,143,290	11/2000	Zhang et al.	424	93.2
	V <sub>B</sub>	5,885,795	3/1999	O'Reilly et al.	435	69.1
	С					
	D					
7	E					-
7	F					
7	G					
7	н					
7	1					
	J					
1	к					
1	L					
†	м					

### FOREIGN PATENT DOCUMENTS

	Document Number Country Code-Number-Kind Code	Date MM-YYYY¹	Country	Name	Classification <sup>2</sup>
N					
Р					
۵				•	
R					
s					
Ŧ					

## **NON-PATENT DOCUMENTS**

•		
_	*	Include, as applicable: Author, Title, Date, Publisher, Edition or Volume, Pertinent Pages
SDP	x	Tanaka et al., "Viral vector-mediated transduction of modified platelet factor 4 cDNA inhibits angiog nesis and tumor growth," Nature Med. 3 (4): 437-442, April 5, 1997.
ļt ;	×	Tanaka et al., "Retrovral and adenoviral mediated transduction fo angiostatin cDNA inhibits angiogenesis and tumor growth," Proc. Amer. Assoc. Cancer Res. 38: 264, March 1997.
-	V	
	,	·

A copy of this reference is not being furnished with this Office action. See MPEP \$ 707.05(a).

<sup>1</sup> Dates in MM-YYYY format are publication dates.

<sup>2</sup> Classifications may be U.S. or foreign.

. S. Patent and Trademerk Office 'TO-892 (Rev. 01-2001)

Notic of References Cited

Part of Paper No. 25

Sorth D. Priche

12/5/05

PTD-1449